Background: Incorporation of HPV tests into cervical cancer screening programs may be advantageous over conventional cytology, especially in developing nations, where the largest burden of cervical cancer is observed....Background: Incorporation of HPV tests into cervical cancer screening programs may be advantageous over conventional cytology, especially in developing nations, where the largest burden of cervical cancer is observed. Objectives: To conduct an evaluation of commercially available molecular HPV tests in Brazilian women. Study design: Two groups were recruited: group A was composed of 511 women referred to the clinics because of a previous abnormal Pap test while group B consisted of 2464 subjects under routine screening. Cervical samples were collected using SurePath liquid cytology (LBC) device, and split into aliquots which were submitted to molecular testing by Hybrid Capture and cobas HPV. Colposcopy and biopsies were made according to the standard guidelines, directed by cytological diagnosis. Results: Prevalence of HSIL was 5.97% and 0.7% in Group A and B respectively. High-Risk HPV DNA was found in about 9% of group B women, while in group A this frequency was 24%. Having CIN3+ as the study end-point, the negative predictive values for molecular methods were above 99.8%. All “in-situ” and invasive cervical carcinomas were detected by both HPV nucleic acid assays. Conclusion: Use of HPV DNA testing was feasible and highly sensitive in cancer screening settings of Brazil.展开更多
We submitted 437 patients with cytological alterations that suggest viral infections to HPV test. 154 patients (35.24%) resulted positive for HPV;among these, 128 (83.11%) with a low degree of infectivity, 19 (12.33%)...We submitted 437 patients with cytological alterations that suggest viral infections to HPV test. 154 patients (35.24%) resulted positive for HPV;among these, 128 (83.11%) with a low degree of infectivity, 19 (12.33%), with an average degree of infectivity and 7 (4.54%) with a high degree of infectivity).展开更多
基金This study was supported by research funds granted to the INCT-HPV(www.hpv.org.br)by the Conselho Nacional de Pesquisas(CNPq,Grant#573799/2008-3) Fundacao de Amparo a Pesquisa do Estado de Sao Paulo(FAPESP,Grant#2008/57889-1)All commercial tests employed were purchased by the INCT-HPV.Companies didn’t have any role in the study design,data evaluation or manuscript writing.
文摘Background: Incorporation of HPV tests into cervical cancer screening programs may be advantageous over conventional cytology, especially in developing nations, where the largest burden of cervical cancer is observed. Objectives: To conduct an evaluation of commercially available molecular HPV tests in Brazilian women. Study design: Two groups were recruited: group A was composed of 511 women referred to the clinics because of a previous abnormal Pap test while group B consisted of 2464 subjects under routine screening. Cervical samples were collected using SurePath liquid cytology (LBC) device, and split into aliquots which were submitted to molecular testing by Hybrid Capture and cobas HPV. Colposcopy and biopsies were made according to the standard guidelines, directed by cytological diagnosis. Results: Prevalence of HSIL was 5.97% and 0.7% in Group A and B respectively. High-Risk HPV DNA was found in about 9% of group B women, while in group A this frequency was 24%. Having CIN3+ as the study end-point, the negative predictive values for molecular methods were above 99.8%. All “in-situ” and invasive cervical carcinomas were detected by both HPV nucleic acid assays. Conclusion: Use of HPV DNA testing was feasible and highly sensitive in cancer screening settings of Brazil.
文摘We submitted 437 patients with cytological alterations that suggest viral infections to HPV test. 154 patients (35.24%) resulted positive for HPV;among these, 128 (83.11%) with a low degree of infectivity, 19 (12.33%), with an average degree of infectivity and 7 (4.54%) with a high degree of infectivity).
